Lucid Diagnostics Reveals Breakthrough in Esophageal Precancer Detection with Largest Real-World Study Results
Lucid Diagnostics Inc., a well-established medical diagnostics company focused on cancer prevention, has recently communicated groundbreaking findings from the most extensive real-world study on esophageal precancer (also known as Barrett's esophagus or BE) detection. This study centers around their innovative testing solution, the EsoGuard® Esophageal DNA Test, combined with the EsoCheck® Esophageal Cell Collection Device. With over 11,000 patients evaluated during routine clinical practices, these results shed substantial light on the effectiveness and efficiency of this non-invasive screening method, positioning it as a vital tool in the battle against esophageal cancer.
The study, aptly titled "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: 18-Month Real-World Experience in 11,991 Patients," has been shared on medRxiv, an esteemed health sciences preprint server. As it undergoes peer review, its authors emphasize the exceptional safety and usability metrics observed. Dr. Lishan Aklog, Lucid's Chairman and CEO, remarked that the results demonstrate a remarkable leap from a theoretical idea to a practical, scalable solution in esophageal cancer prevention.
The research gathered data from nearly 12,000 patients who underwent the EsoCheck procedure and subsequent EsoGuard testing between January 2023 and June 2024. The analysis revealed an impressive 95% success rate for technical performance in cell collection procedures, with nearly all collection processes completed in under two minutes and no significant adverse events reported. Furthermore, a majority of participants met gastroenterology society guidelines for BE screening, showcasing the appropriate utilization of these tools within medical practices.
“This extensive real-world experience demonstrates that EsoGuard has advanced from an aspirational 'missing link' in esophageal cancer prevention to the linchpin of a clinically viable and scalable early detection program,” Dr. Aklog noted. This assertion is bolstered by previously published data that underscored the clinical validity and utility of the EsoGuard testing process.
The successful implementation across diverse clinical environments reflects a well-executed collaboration among Lucid's trained professionals, ensuring efficiency even in less centralized healthcare settings like health fairs. Dr. Victoria T. Lee, CMO of Lucid, emphasized how this wide-ranging data confirms that the EsoGuard and EsoCheck tests are functioning optimally outside clinical trials, affirming the promise of these tools to not just improve patient outcomes but also streamline the process of identifying individuals who would benefit from more invasive procedures.
Lucid Diagnostics remains committed to its mission of enhancing early detection and prevention methodologies, particularly for patients experiencing gastroesophageal reflux disease (GERD) who are at increased risk for esophageal precancer and cancer. As the study outcomes indicate, the EsoGuard® and EsoCheck® solutions are not only poised to lower the incidence of invasive diagnostic approaches but also pave the way for broader acceptance and application across various healthcare landscapes. This could ultimately lead to a significant reduction in esophageal cancer mortality rates, offering hope to millions at risk. For more details about their pioneering work in this field, visit www.luciddx.com.
The ongoing evolution of Lucid Diagnostics, including this new data release, continues to captivate attention among stakeholders, with potential implications for clinical practices and cancer prevention strategies worldwide.
The study, aptly titled "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: 18-Month Real-World Experience in 11,991 Patients," has been shared on medRxiv, an esteemed health sciences preprint server. As it undergoes peer review, its authors emphasize the exceptional safety and usability metrics observed. Dr. Lishan Aklog, Lucid's Chairman and CEO, remarked that the results demonstrate a remarkable leap from a theoretical idea to a practical, scalable solution in esophageal cancer prevention.
The research gathered data from nearly 12,000 patients who underwent the EsoCheck procedure and subsequent EsoGuard testing between January 2023 and June 2024. The analysis revealed an impressive 95% success rate for technical performance in cell collection procedures, with nearly all collection processes completed in under two minutes and no significant adverse events reported. Furthermore, a majority of participants met gastroenterology society guidelines for BE screening, showcasing the appropriate utilization of these tools within medical practices.
“This extensive real-world experience demonstrates that EsoGuard has advanced from an aspirational 'missing link' in esophageal cancer prevention to the linchpin of a clinically viable and scalable early detection program,” Dr. Aklog noted. This assertion is bolstered by previously published data that underscored the clinical validity and utility of the EsoGuard testing process.
The successful implementation across diverse clinical environments reflects a well-executed collaboration among Lucid's trained professionals, ensuring efficiency even in less centralized healthcare settings like health fairs. Dr. Victoria T. Lee, CMO of Lucid, emphasized how this wide-ranging data confirms that the EsoGuard and EsoCheck tests are functioning optimally outside clinical trials, affirming the promise of these tools to not just improve patient outcomes but also streamline the process of identifying individuals who would benefit from more invasive procedures.
Lucid Diagnostics remains committed to its mission of enhancing early detection and prevention methodologies, particularly for patients experiencing gastroesophageal reflux disease (GERD) who are at increased risk for esophageal precancer and cancer. As the study outcomes indicate, the EsoGuard® and EsoCheck® solutions are not only poised to lower the incidence of invasive diagnostic approaches but also pave the way for broader acceptance and application across various healthcare landscapes. This could ultimately lead to a significant reduction in esophageal cancer mortality rates, offering hope to millions at risk. For more details about their pioneering work in this field, visit www.luciddx.com.
The ongoing evolution of Lucid Diagnostics, including this new data release, continues to captivate attention among stakeholders, with potential implications for clinical practices and cancer prevention strategies worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.